Scaling manufacturing and commercialization for an autologous CAR-T therapy like Carvykti is too complex for a small biotech alone. Legend Biotech's partnership with J&J was critical, combining Legend's science with J&J's global manufacturing, clinical development, and commercial muscle.

Investors evaluate risk differently based on a company's stage. For early-stage ventures, the primary question is clinical risk: 'will the drug work?'. CMC and manufacturing are secondary. However, for late-stage (Phase 3) companies, manufacturing readiness becomes a critical diligence area where a two-year delay could be fatal.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

The inflection point for a novel manufacturing platform's credibility isn't just an initial IND or a niche approval. It's achieving late-stage (Phase 2/3) clinical data in a major new therapeutic category, like oncology monoclonal antibodies. This signal fundamentally changes the risk calculus for both regulators and industry adopters.

To avoid common gene therapy manufacturing delays, Ray Therapeutics invested heavily in its Chemistry, Manufacturing, and Controls (CMC) process early. They established a commercial-scale process *before* dosing a single patient, eliminating the risky and time-consuming transition from clinical to commercial material.

J&J overcame skepticism about Legend's impressive but China-based CAR-T data by conducting deep, on-the-ground due diligence. They reviewed patient records and documentation to confirm the data's integrity, which became the foundation for a highly successful global partnership.

Legend's R&D model leverages early-stage, investigator-led trials in China to generate clinical data rapidly. This approach allows the company to make quicker, more informed decisions about which programs to advance into larger, global development, creating a more efficient and data-driven pipeline.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.

Unlike tech VC, where revenue and users are key metrics, the fundamental currency for an early-stage biotech investment is clinical data. The entire investment thesis revolves around the efficiency and likelihood of translating a novel biological insight into human clinical validation.